PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE:	**1/01/16**
LAST REVIEW DATE:	**9/20/18**
LAST CRITERIA REVISION DATE:	**9/20/18**
ARCHIVE DATE:	

XTANDI® (enzalutamide) oral capsule

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as "Description" defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as "Criteria" defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

This Pharmacy Coverage Guideline does not apply to FEP or other states' Blues Plans.

Information about medications that require precertification is available at www.azblue.com/pharmacy.

Some large (100+) benefit plan groups may customize certain benefits, including adding or deleting precertification requirements.

All applicable benefit plan provisions apply, e.g., waiting periods, limitations, exclusions, waivers and benefit maximums.

Precertification for medication(s) or product(s) indicated in this guideline requires completion of the request form in its entirety with the chart notes as documentation. All requested data must be provided. Once completed the form must be signed by the prescribing provider and faxed back to BCBSAZ Pharmacy Management at (602) 864-3126 or emailed to Pharmacyprecert@azblue.com. **Incomplete forms or forms without the chart notes will be returned.**

XTANDI® (enzalutamide) oral capsule (cont.)

Criteria:

- **Criteria for initial therapy:** Xtandi is considered ***medically necessary*** and will be approved when **ALL** of the following criteria are met:

  1. Prescriber is an Oncologist
  2. Individual is male and 18 years of age or older
  3. A confirmed diagnosis of **ONE** of the following:
     - Metastatic castration-resistant prostate cancer
     - Other request for a specific oncologic direct treatment use that is found and listed in the National Comprehensive Cancer Network (NCCN) Guidelines with Categories of Evidence and Consensus of 1, 2A, or 2B

  Initial approval duration: 6 months

- **Criteria for continuation of coverage (renewal request):** Xtandi is considered ***medically necessary*** and will be approved with documentation of **ALL** of the following:

  1. Continues to be seen by an Oncologist
  2. The cancer has not progressed while on therapy
  3. Individual has been adherent with the medication
  4. Individual has not developed any significant level 4 adverse drug effects that may exclude continued use, such as:
     - Posterior reversible encephalopathy syndrome (PRES) with Xtandi
     - Seizure while on Xtandi
  5. There are no significant interacting drugs

  Renewal duration: 12 months

Description:

Xtandi (enzalutamide) is an androgen receptor inhibitor that is indicated for **the treatment of metastatic castration-resistant prostate cancer**.

XTANDI® (enzalutamide) oral capsule (cont.)

Enzalutamide acts on different steps in the androgen receptor signaling pathway. It has been shown to competitively inhibit androgen binding to androgen receptors and inhibit androgen receptor nuclear translocation and interaction with deoxyribonucleic acid (DNA). Enzalutamide decreased proliferation and induced cell death of prostate cancer cells *in vitro*, and decreased tumor volume in a mouse prostate cancer xenograft model.

Resources:

Xtandi. Package Insert. Revised by manufacturer 7/2015. Accessed 08-04-2015.

Xtandi. Package Insert. Revised by manufacturer 10/2015. Accessed 07-26-2016.

Xtandi. Package Insert. Revised by manufacturer 10/2016. Accessed 08-25-2017.

Xtandi. Package Insert. Revised by manufacturer 7/2017. Accessed 07-19-2018.

NCCN Clinical Practice Guidelines in Oncology: Prostate cancer. Version 2.2017, Feb 21. 2017. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

NCCN Clinical Practice Guidelines in Oncology: Prostate cancer. Version 4.2018, Aug 15. 2018. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

UpToDate: Prostate cancer: Risk stratification and choice of initial treatment. Current through Aug 2017. https://www-uptodate-com.mwu.idm.oclc.org/contents/prostate-cancer-risk-stratification-and-choice-of-initial-treatment?source=search_result&search=prostate%20cancer&selectedTitle=1~150#H19

UpToDate: Overview of the treatment of castration-resistant prostate cancer (CRPC). Current through Aug 2017. https://www-uptodate-com.mwu.idm.oclc.org/contents/overview-of-the-treatment-of-castration-resistant-prostate-cancer-crpc?source=search_result&search=prostate%20cancer&selectedTitle=3~150

Off Label Use of Cancer Medications: A.R.S. §§ 20-826(R) & (S). Subscription contracts; definitions.

Off Label Use of Cancer Medications: A.R.S. §§ 20-1057(V) & (W). Evidence of coverage by health care service organizations; renewability; definitions.

Fax completed prior authorization request form to 602-864-3126 or email to pharmacyprecert@azblue.com.
Call 866-325-1794 to check the status of a request.
All requested data must be provided. **Incomplete forms or forms without the chart notes will be returned**.
Pharmacy Coverage Guidelines are available at www.azblue.com/pharmacy.

Pharmacy Prior Authorization Request Form

Do not copy for future use. Forms are updated frequently.
REQUIRED: Office notes, labs, and medical testing relevant to the request that show medical justification are required.

Member Information

Member Name (first & last):	Date of Birth:	Gender:	BCBSAZ ID#:
Address:	City:	State:	Zip Code:

Prescribing Provider Information

Provider Name (first & last):	Specialty:	NPI#:	DEA#:
Office Address:	City:	State:	Zip Code:
Office Contact:	Office Phone:		Office Fax:

Dispensing Pharmacy Information

Pharmacy Name:	Pharmacy Phone:	Pharmacy Fax:

Requested Medication Information

Medication Name:	Strength:		Dosage Form:
Directions for Use:	Quantity:	Refills:	Duration of Therapy/Use:

☐ Check if requesting **brand** only ☐ Check if requesting **generic**

☐ Check if requesting continuation of therapy (prior authorization approved by BCBSAZ expired)

Turn-Around Time For Review

☐ Standard ☐ Urgent. Sign here: ________________________________ ☐ Exigent (requires prescriber to include a written statement)

Clinical Information

1. What is the diagnosis? Please specify below.

ICD-10 Code: ____________________ **Diagnosis Description:** ______________________________

2. ☐ Yes ☐ No **Was this medication started on a recent hospital discharge or emergency room visit?**

3. ☐ Yes ☐ No **There is absence of ALL contraindications.**

4. What medication(s) has the individual tried and failed for this diagnosis? Please specify below.
Important note: Samples provided by the provider are not accepted as continuation of therapy or as an adequate trial and failure.

Medication Name, Strength, Frequency	Dates started and stopped or Approximate Duration	Describe response, reason for failure, or allergy

5. Are there any supporting labs or test results? Please specify below.

Date	Test	Value

BlueCross BlueShield of Arizona

An Independent Licensee of the Blue Cross and Blue Shield Association

Pharmacy Prior Authorization Request Form

6. Is there any additional information the prescribing provider feels is important to this review? Please specify below.
For example, explain the negative impact on medical condition, safety issue, reason formulary agent is not suitable to a specific medical condition, expected adverse clinical outcome from use of formulary agent, or reason different dosage form or dose is needed.

Signature affirms that information given on this form is true and accurate and reflects office notes	
Prescribing Provider's Signature:	Date:

Please note: Some medications may require completion of a drug-specific request form.

Incomplete forms or forms without the chart notes will be returned.

Office notes, labs, and medical testing relevant to the request that show medical justification are required.